XML 34 R21.htm IDEA: XBRL DOCUMENT
v3.23.2

ACQUISITION-RELATED (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER | 6 Months Ended
--- | ---
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
ACQUISITION-RELATED (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER | ACQUISITION-RELATED (GAINS) CHARGES, RESTRUCTURING CHARGES AND OTHER Acquisition-related (gains) charges, restructuring charges and other for the three and six months ended June 30, 2023 and 2022 summarized below (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Severance-related expenses | $ | — |  |  | $ | 950 |  |  | $ | — |  |  | $ | 4,065 |
Acquisition-related fees | 709 |  |  | 2,168 |  |  | 1,198 |  |  | 4,013 |
Other acquisition expenses | — |  |  | 104 |  |  | — |  |  | 552 |
Total acquisition-related charges | 709 |  |  | 3,222 |  |  | 1,198 |  |  | 8,630 |
Flexion contingent consideration | (18,258) |  |  | (12,523) |  |  | (6,640) |  |  | (13,317) |
MyoScience contingent consideration | — |  |  | (8,757) |  |  | — |  |  | (9,034) |
Restructuring charges | 936 |  |  | — |  |  | 936 |  |  | — |
Total acquisition-related (gains) charges, restructuring charges and other | $ | (16,613) |  |  | $ | (18,058) |  |  | $ | (4,506) |  |  | $ | (13,721) |
Flexion Acquisition The Company recognized acquisition-related costs of $0.7 million and $1.2 million during the three and six months ended June 30, 2023, respectively, primarily related to the remaining Flexion leases. The Company recognized acquisition-related costs of $3.2 million and $8.6 million during the three and six months ended June 30, 2022, respectively, primarily related to severance, legal fees, third-party services and other one-time charges. The Company recognized $18.3 million and $6.6 million contin gent consideration gains during the three and six months ended June 30, 2023, respectively. The Company recognized $12.5 million and $13.3 million of contingent consideration gains during the three and six months ended June 30, 2022, respectively. See Note 9, Financial Instruments, for information regarding the method, key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value. MyoScience Acquisition The Company recognized $8.8 million and $9.0 million of contingent consideration gains during the three and six months ended June 30, 2022, respectively. See Note 9, Financial Instruments, for information regarding the method, key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value. Restructuring Charges In J une 2023, t he Company implemented a restructuring plan in an effort to improve its operational efficiencies. The restructuring charges are predominantly related to one-time employee termination benefits through a reduction of headcount, such as severance and related costs. During the three and six months ended June 30, 2023, t he Company recognized $0.9 million of restructuring charges, of which $0.4 million was paid. The remaining $0.5 million is expected to be paid in the third quarter of 2023.

X
- Definition The entire description for costs incurred to effect a business combination that have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//805/tableOfContent + Details
Name: | us-gaap_BusinessAcquisitionIntegrationRestructuringAndOtherRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration